SEC Info  
    Home      Search      My Interests      Help      Sign In      Please Sign In

10x Genomics, Inc. – ‘10-Q’ for 6/30/22

On:  Monday, 8/8/22, at 7:30pm ET   ·   As of:  8/9/22   ·   For:  6/30/22   ·   Accession #:  1770787-22-49   ·   File #:  1-39035

Previous ‘10-Q’:  ‘10-Q’ on 5/5/22 for 3/31/22   ·   Next:  ‘10-Q’ on 11/3/22 for 9/30/22   ·   Latest:  ‘10-Q’ on 11/3/23 for 9/30/23   ·   5 References:   

Find Words in Filings emoji
 
  in    Show  and   Hints

  As Of               Filer                 Filing    For·On·As Docs:Size

 8/09/22  10x Genomics, Inc.                10-Q        6/30/22   56:5.4M

Quarterly Report   —   Form 10-Q

Filing Table of Contents

Document/Exhibit                   Description                      Pages   Size 

 1: 10-Q        Quarterly Report                                    HTML   1.08M 
 2: EX-10.1     Material Contract                                   HTML    133K 
 3: EX-31.1     Certification -- §302 - SOA'02                      HTML     22K 
 4: EX-31.2     Certification -- §302 - SOA'02                      HTML     22K 
 5: EX-32.1     Certification -- §906 - SOA'02                      HTML     19K 
 6: EX-32.2     Certification -- §906 - SOA'02                      HTML     19K 
12: R1          Cover Page                                          HTML     74K 
13: R2          Condensed Consolidated Balance Sheets               HTML    128K 
14: R3          Condensed Consolidated Statements of Operations     HTML    102K 
15: R4          Condensed Consolidated Statements of Comprehensive  HTML     46K 
                Loss                                                             
16: R5          Condensed Consolidated Statements of Stockholders?  HTML     79K 
                Equity                                                           
17: R6          Condensed Consolidated Statements of Cash Flows     HTML    120K 
18: R7          Description of Business and Basis of Presentation   HTML     24K 
19: R8          Summary of Significant Accounting Policies          HTML     30K 
20: R9          Other Financial Statement Information               HTML    107K 
21: R10         Commitments and Contingencies                       HTML     38K 
22: R11         Capital Stock                                       HTML     24K 
23: R12         Equity Incentive Plans                              HTML     48K 
24: R13         Net Loss Per Share                                  HTML     34K 
25: R14         Subsequent Events                                   HTML     20K 
26: R15         Summary of Significant Accounting Policies          HTML     43K 
                (Policies)                                                       
27: R16         Other Financial Statement Information (Tables)      HTML    120K 
28: R17         Commitments and Contingencies (Tables)              HTML     33K 
29: R18         Equity Incentive Plans (Tables)                     HTML     50K 
30: R19         Net Loss Per Share (Tables)                         HTML     33K 
31: R20         Summary of Significant Accounting Policies -        HTML     19K 
                Additional Information (Detail)                                  
32: R21         Other Financial Statement Information -             HTML     47K 
                Available-for-Sale Securities (Details)                          
33: R22         Other Financial Statement Information - Additional  HTML     36K 
                Information (Detail)                                             
34: R23         Other Financial Statement Information -             HTML     36K 
                Contractual Maturities of Marketable Securities                  
                (Details)                                                        
35: R24         Other Financial Statement Information - Schedule    HTML     28K 
                of Inventory (Detail)                                            
36: R25         Other Financial Statement Information - Schedule    HTML     34K 
                of Accrued Compensation and Related Benefits                     
                (Detail)                                                         
37: R26         Other Financial Statement Information - Schedule    HTML     40K 
                of Accrued Expense And Other Current Liabilities                 
                (Detail)                                                         
38: R27         Other Financial Statement Information - Schedule    HTML     25K 
                of Changes in the Reserve for Product Warranties                 
                (Detail)                                                         
39: R28         Other Financial Statement Information - Revenue     HTML     22K 
                Recognition (Details)                                            
40: R29         Other Financial Statement Information - Schedule    HTML     30K 
                of Revenue by Source (Detail)                                    
41: R30         Other Financial Statement Information - Schedule    HTML     35K 
                of Revenue by Geographic Region (Details)                        
42: R31         Commitments and Contingencies - Additional          HTML     24K 
                Information (Detail)                                             
43: R32         Commitments and Contingencies - Summary of          HTML     40K 
                Company's Operating Lease Liabilities (Detail)                   
44: R33         Commitments and Contingencies - Summary of          HTML     22K 
                Additional Information Related to Operating Leases               
                (Detail)                                                         
45: R34         Capital Stock - Additional Information (Detail)     HTML     32K 
46: R35         Equity Incentive Plans - Additional Information     HTML     29K 
                (Detail)                                                         
47: R36         Equity Incentive Plans - Recorded Stock-Based       HTML     28K 
                Compensation Expense in the Condensed Consolidated               
                Statement of Operations (Details)                                
48: R37         Equity Incentive Plans - Summary of RSU Activity    HTML     41K 
                (Detail)                                                         
49: R38         Equity Incentive Plans - Summary of Company's       HTML     41K 
                Stock Option Activity (Details)                                  
50: R39         Net Loss Per Share - Shares of Common Stock         HTML     35K 
                Equivalents Were Excluded From The Computation of                
                Diluted Net Loss Per Share (Details)                             
51: R40         Subsequent Events (Details)                         HTML     26K 
54: XML         IDEA XML File -- Filing Summary                      XML     95K 
52: XML         XBRL Instance -- txg-20220630_htm                    XML   1.08M 
53: EXCEL       IDEA Workbook of Financial Reports                  XLSX     82K 
 8: EX-101.CAL  XBRL Calculations -- txg-20220630_cal                XML    179K 
 9: EX-101.DEF  XBRL Definitions -- txg-20220630_def                 XML    258K 
10: EX-101.LAB  XBRL Labels -- txg-20220630_lab                      XML   1.06M 
11: EX-101.PRE  XBRL Presentations -- txg-20220630_pre               XML    571K 
 7: EX-101.SCH  XBRL Schema -- txg-20220630                          XSD     99K 
55: JSON        XBRL Instance as JSON Data -- MetaLinks              291±   441K 
56: ZIP         XBRL Zipped Folder -- 0001770787-22-000049-xbrl      Zip    496K 




        
Filing Submission 0001770787-22-000049 – SGML Text

Original SGML Text submitted by:  10x Genomics, Inc.

To view the SGML, please refresh
Refresh emoji
this page.


Top

Copyright © 2024 Fran Finnegan & Company LLC – All Rights Reserved.
AboutPrivacyRedactionsHelp — Sun., Apr. 28, 7:51:52.2pm ET